Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 14/20 | 0.72 |
| ▸ | GRM5 | P41594 | 12/20 | 0.72 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.42 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | LIPC | P11150 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30746011 | 1.00 | GRM1 (0.72) | GRM1GRM5NAMPTSOS1PDK4 | |
| SCHEMBL27007916 | 0.96 | GRM1 (0.67) | GRM1GRM5NAMPTSOS1PDK4 | |
| SCHEMBL27007743 | 0.86 | GRM1 (0.78) | GRM1GRM5NAMPTPDK4 | |
| SCHEMBL30746004 | 0.85 | GRM1 (0.68) | GRM1GRM5NAMPTSOS1PDK4 | |
| SCHEMBL27007877 | 0.85 | GRM1 (0.68) | GRM1GRM5NAMPTSOS1PDK4 | |
| SCHEMBL30745993 | 0.84 | GRM1 (0.67) | GRM1GRM5NAMPTPDK4 | |
| SCHEMBL27007835 | 0.84 | GRM1 (0.67) | GRM1GRM5NAMPTPDK4 | |
| SCHEMBL27025918 | 0.84 | GRM1 (0.64) | GRM1GRM5NAMPTPDK4CDK7 | |
| SCHEMBL27025917 | 0.84 | GRM1 (0.52) | GRM1GRM5NAMPTSOS1WNT3A | |
| SCHEMBL2890770 | 0.83 | GRM1 (1.00) | GRM1GRM5NAMPTPDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018121-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMCIAL DIVERSITY CENTER, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018121-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMCIAL DIVERSITY CENTER, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018121-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMCIAL DIVERSITY CENTER, INC. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018121-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | ERG28, CYP51A1, MANBA | GRM1 2602/4885GRM5 3764/4885NAMPT 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.